GlassScriptPhysician profile
Marc A Weitzel
NPI 1669469565
$3,614.25
in general payments reported to CMS, 2019-2025
24 companies · $539 in 2025
The $539 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $387 · 2021: $623 · 2022: $368 · 2023: $867 · 2024: $549 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $670.99 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $483.17 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $405.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $375.32 | 2019-2025 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $344.44 | 2021-2025 | Verquvo, Belsomra |
| Abbott Laboratories | $192.65 | 2020-2025 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $164.91 | 2023 | Micra, Cobalt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $152.71 | 2021-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $146.80 | 2019-2025 | |
| Novo Nordisk INC | $127.82 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $99.39 | 2021-2025 | Nexletol |
| Abiomed | $70.26 | 2022-2023 | Impella |
| Impulse Dynamics (USA) INC. | $69.44 | 2024-2025 | Optimizer |
| Pfizer INC. | $41.21 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $38.22 | 2023-2024 | Assure Wcd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $29.81 | 2023 | Zio Xt Patch |
| Shockwave Medical, INC | $29.29 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Actelion Pharmaceuticals US, INC. | $27.85 | 2021 | |
| Scpharmaceuticals INC. | $25.84 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $25.45 | 2023 | Arcalyst |
| Athena Bioscience, LLC | $25.36 | 2025 | Nexiclon Xr |
| Daiichi Sankyo INC. | $24.36 | 2024 | Injectafer |
| Lilly USA, LLC | $22.21 | 2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $20.90 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Weitzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.